Cancer multi-omics-based differential expression analysis and prognostic potential of identified hub targets of myco-metabolites for breast carcinoma and lung carcinoma

被引：0

作者：

Shreya, Singh ^{[1
,2
]}

Mohapatra, Debadatta ^{[1
,3
]}

Naik, Gaurav Gopal ^{[1
,4
]}

Kathait, Pooja ^{[1
]}

Malang, Soki ^{[1
]}

Patel, Pradeep ^{[1
]}

Shambhavi, Gulzar

Alam, Gulzar ^{[2
]}

Sahu, Alakh N. ^{[1
]}

机构：

[1] Indian Inst Technol BHU, Dept Pharmaceut Engn & Technol, Phytomed Res Lab, Varanasi 221005, India

[2] SBS Coll Pharm, Fatehpur 212664, India

[3] Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON M5S 3M2, Canada

[4] Yashwantrao Bhonsale Coll Pharm, Sawantwadi 416510, Maharashtra, India

来源：

FUTURE JOURNAL OF PHARMACEUTICAL SCIENCES | 2025年 / 11卷 / 01期

关键词：

Breast carcinoma; GEPIA2; KM plotter; Lung carcinoma; Network pharmacology; UALCAN; TAMOXIFEN RESISTANCE; RECEPTOR;

D O I：

10.1186/s43094-025-00768-9

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

BackgroundBreast carcinoma (BC) and lung carcinoma (LC) have the highest incidence and mortality rates worldwide. In prior work, studied sample hub targets contributing to anticancer potential against BC and LC were identified through network pharmacology. In the present work, web servers UALCAN, GEPIA2, and KM plotter were used to explore the genomic and proteomic expression of these hub targets, along with their prognosis potential in BC and LC.ResultsDifferential hub targets SRC, MAPK3, PTPN11, JAK2, ESR1, and HAP900A1 for BC and PTPN11, JAK2, ESR1, EGFR, and MAPK3 for LC, showed good prognostic potentials. Collectively, PTPN11, JAK2, and ESR1 were overlapped differential expressed hub targets involved in the significantly good prognosis of both carcinoma.ConclusionThese differentially expressed hub targets may be taken into account for future BC and LC treatments due to their strong prognostic potential.

引用

页数：8

共 18 条

[1] Geldanamycins: Potent Hsp90 Inhibitors with Significant Potential in Cancer Therapy [J].